NCT00367237 - Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422) | Biotech Hunter

Enrollment

115

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Arthritis, Psoriatic

Interventions

DRUG

Infliximab + methotrexate (IFX + MTX)

Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.

DRUG

Methotrexate (MTX)

Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.